A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
| 対象疾患 | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer |
|---|---|
| 相 | 第2相 |
| スポンサー | Compass Therapeutics |
| ステータス | 完了 |
| 参加者数 | 49 名 |
| 介入（薬剤） | CTX-009 |
| 開始日 | 2022年12月8日 |
| 完了日 | 2025年5月15日 |
| 結果公開日 | 2026年7月28日 |
概要
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.
Overall Response Rate
| CTX-009 10 mg/kg | 2 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- CryoBalloon Ablation for Treatment of Duodenal Adenomas — Johns Hopkins University
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps — National Cancer Institute (NCI)
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal — National Cancer Institute (NCI)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)